Nature Metabolism Клеточная биология

Plasma proteomics identifies insulin resistance signatures predictive of cardiometabolic disease risk

Kjærgaard, Jeppe, Kurgan, Nigel, Gräf, Justus F., Zhang, Naixin, Wang, Zhe, Custódio, Mafalda Da Cruz, Schlabs, Farina, Pisano, Paola, Ottander, Lisa, Petersen, Maria Houborg, Almeida, Martin Eisemann, Stidsen, Jacob, Merino, Jordi, Kilpeläinen, Tuomas O., Ørtenblad, Niels, Rydén, Mikael, Rasmussen, Simon, Krook, Anna, Guasch-Ferré, Marta, Loos, Ruth J. F., Smit, Roelof A. J., Højlund, Kurt, Zierath, Juleen R., Wierer, Michael, Deshmukh, Atul S.
Springer Nature · 2026-11-16 · DOI 10.1038/s42255-026-01662-1

Аннотация

Insulin resistance drives cardiometabolic disease, yet its molecular signatures and tissue origins remain incompletely characterized. Here we define a circulating protein signature that enables scalable assessment of insulin sensitivity. We applied multiworkflow proteomics to plasma from 161 individuals spanning the insulin sensitivity spectrum defined by the hyperinsulinaemic–euglycaemic clamp and identified 488 proteins associated with insulin sensitivity, capturing contributions from liver, adipose tissue and immune cells. A subset of these proteins shifted towards a more insulin-sensitive profile following an exercise intervention in men. We further developed a model combining 13 proteins, including IGFBP1, LEP, GDF15, PON3 and LDLR, with clinical variables (sex, HbA1c and the triglyceride-to-high-density lipoprotein cholesterol ratio) to predict insulin sensitivity ( R ^2 = 0.67). In ~20,000 UK Biobank participants, the model outperformed the triglyceride-to-high-density lipoprotein cholesterol ratio in predicting type 2 diabetes (concordance index, 0.86 versus 0.74) and, unlike HbA1c, predicted hepatic, renal, cardiovascular and respiratory disease. In an independent cohort of 1,700 individuals, the model also showed greater predictive utility than fasting insulin resistance indices, including the homeostatic model assessment of insulin resistance. Together, these findings establish a tissue-resolved plasma proteomic framework for characterizing insulin resistance and provide a scalable approach to precision cardiometabolic risk stratification. Integration of deep plasma proteomics with hyperinsulinaemic–euglycaemic clamp measurements enables the generation of a tissue-resolved molecular atlas of insulin resistance. A model derived from these signatures outperforms conventional surrogate markers in predicting cardiometabolic disease across large population cohorts.

Читать у издателя →